FDA Prop 65 NRT Warning Rejection Should Be Given Deference, Firms Say
This article was originally published in The Tan Sheet
Executive Summary
FDA's view that a Prop 65 pregnancy warning on OTC nicotine replacement therapies is "without scientific foundation" should be given more weight, NRT firms assert in a brief filed in California Supreme Court Jan. 21
You may also be interested in...
NRT Firms’ Deference To “Informal” FDA Letters In Prop 65 Case Improper
NRT firms' reliance on "unpublished, ad hoc" FDA statements to support their contention that a Proposition 65 warning on OTC smoking cessation products conflicts with federal law is improper, according to a brief filed in California Supreme Court April 15
Nicotine Replacement Therapy Prop 65 Warning Unfounded, FDA Tells Court
A California appellate court's ruling that a Prop 65 warning for nicotine replacement therapies is not federally preempted would require product manufacturers to use warning language FDA has determined lacks scientific support, the agency says
Prop 65 Smoking Cessation Warnings Not In Conflict With FDA Rules – Court
FDA's newly revised pregnancy warning for OTC smoking cessation products could be expanded to include a statement regarding fetal harm as required under Proposition 65, a San Francisco appellate judge says